Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.